ArticleFrontiers in microbiology2022
Ginsenoside Rb1 Improves Metabolic Disorder in High-Fat Diet-Induced Obese Mice Associated With Modulation of Gut Microbiota.
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- The Efficacy ofNutrients · 2023Pooled it
- Ginsenoside Rb1: From basic mechanisms to therapeutic applications in diabetic complications.Journal of ginseng research · 2026Review
- Microbiome-mediated pharmacology of ginseng: Mechanistic insights into metabolic regulation and therapeutic potential.Journal of ginseng research · 2026Review
- Ginsenoside Rb1 mitigates senescence-associated hepatic steatosis in mice through enhanced lysine degradation.Journal of ginseng research · 2026Article
- Gut microbiota-liver-kidney axis in diabetic kidney disease: mechanistic insights into amino acid metabolism and nutritional intervention strategies targeting natural bioactive compounds.Frontiers in nutrition · 2026Review
- Research progress on the relationship and mechanisms of obesity, gut microbiota, and natural medicines.Frontiers in endocrinology · 2026Review
- Ginseng and its active compounds in ovarian aging: mechanistic basis and translational prospects.Frontiers in pharmacology · 2026Review
- Article
- Unlocking ginsenosides' therapeutic power with polymer-based delivery systems: current applications and future perspectives.Frontiers in pharmacology · 2025Review
- Gut microbiota and its metabolites regulate insulin resistance: traditional Chinese medicine insights for T2DM.Frontiers in microbiology · 2025Review
- Gut dysbiosis was inevitable, but tolerance was not: temporal responses of the murine microbiota that maintain its capacity for butyrate production correlate with sustained antinociception to chronic morphine.bioRxiv : the preprint server for biology · 2024Article
- Impact of ginsenoside Rb1 on gut microbiome and associated changes in pharmacokinetics in rats.Scientific reports · 2024Article
- Effects of Ginsenoside Rb1 on the Crosstalk between Intestinal Stem Cells and Microbiota in a Simulated Weightlessness Mouse Model.International journal of molecular sciences · 2024Article
- Ginsenoside Rb1, Compound K and 20(S)-Protopanaxadiol Attenuate High-Fat Diet-Induced Hyperlipidemia in Rats via Modulation of Gut Microbiota and Bile Acid Metabolism.Molecules (Basel, Switzerland) · 2024Article
- A mediation analysis of the role of total free fatty acids on pertinence of gut microbiota composition and cognitive function in late life depression.Lipids in health and disease · 2024Article
- Traditional Chinese medicine to improve immune imbalance of asthma: focus on the adjustment of gut microbiota.Frontiers in microbiology · 2024Review
- Ginsenoside Rb1 Interfered with Macrophage Activation by Activating PPARγ to Inhibit Insulin Resistance in Obesity.Molecules (Basel, Switzerland) · 2023Article
- Hypolipidemic effect and molecular mechanism of ginsenosides: a review based on oxidative stress.Frontiers in pharmacology · 2023Review
- Article
- Gut Microbes Are Associated with the Vascular Beneficial Effects of Dietary Strawberry on Metabolic Syndrome-Induced Vascular Inflammation.Molecular nutrition & food research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gut microbiota plays an important role in metabolic homeostasis. Previous studies demonstrated that ginsenoside Rb1 might improve obesity-induced metabolic disorders through regulating glucose and lipid metabolism in the liver and adipose tissues. Due to low bioavailability and enrichment in the intestinal tract of Rb1, we hypothesized that modulation of the gut microbiota might account for its pharmacological effects as well. Here, we show that oral administration of Rb1 significantly decreased serum LDL-c, TG, insulin, and insulin resistance index (HOMA-IR) in mice with a high-fat diet (HFD). Dynamic profiling of the gut microbiota showed that this metabolic improvement was accompanied by restoring of relative abundance of some key bacterial genera. In addition, the free fatty acids profiles in feces were significantly different between the HFD-fed mice with or without Rb1. The content of eight long-chain fatty acids (LCFAs) was significantly increased in mice with Rb1, which was positively correlated with the increase of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.